Cidara Therapeutics (CDTX) Competitors

Cidara Therapeutics (NASDAQ:CDTX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Do institutionals and insiders have more ownership in CDTX or AXSM?

35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 3.9% of Cidara Therapeutics shares are held by company insiders. Comparatively, 22.3% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media refer more to CDTX or AXSM?

In the previous week, Axsome Therapeutics had 6 more articles in the media than Cidara Therapeutics. MarketBeat recorded 26 mentions for Axsome Therapeutics and 20 mentions for Cidara Therapeutics. Cidara Therapeutics' average media sentiment score of 0.80 beat Axsome Therapeutics' score of 0.38 indicating that Cidara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cidara Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has higher valuation and earnings, CDTX or AXSM?

Cidara Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cidara Therapeutics	$1.27M	1,269.00	-$169.83M	-$11.13	-5.71
Axsome Therapeutics	$385.69M	14.07	-$287.22M	-$5.07	-21.45

Which has more risk & volatility, CDTX or AXSM?

Cidara Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Do analysts rate CDTX or AXSM?

Cidara Therapeutics presently has a consensus target price of $64.14, indicating a potential upside of 0.93%. Axsome Therapeutics has a consensus target price of $178.00, indicating a potential upside of 63.68%. Given Axsome Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Cidara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cidara Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07

Is CDTX or AXSM more profitable?

Cidara Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -49.88%. Cidara Therapeutics' return on equity of -50.81% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cidara Therapeutics	N/A	-50.81%	-42.46%
Axsome Therapeutics	-49.88%	-283.22%	-33.06%

Summary

Cidara Therapeutics and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.